论文部分内容阅读
目的:评价依达拉奉联合疏血通注射液治疗急性脑梗死大鼠的疗效和安全性。方法:将SD大鼠随机分为:假手术组、模型组、依达拉奉组、疏血通组、依达拉奉联合疏血通组,采用线栓法复制大鼠左侧大脑中动脉脑缺血(middle cerebral artery occlusion,MCAO)模型,除假手术组外,每组按不同时间点(1、3、5、7d)分为4个亚组,术后各组腹腔注射相应药物,1次/d,连续给药1、3、5、7d,模型组、假手术组分别予以等体积0.9%氯化钠溶液,观察比较各组大鼠神经功能缺损评分、脑组织梗死体积、脑组织含水量、脑组织形态学改变及白细胞计数(WBC)、谷丙转氨酶(ALT)、谷草转氨酶(AST)、肌酐(Cr)、尿素氮(BUN)、磷酸肌酸激酶(CK)、乳酸脱氢酶(LDH)、活化部分凝血活酶时间(APTT)等变化。结果:与假手术组比较,其余各组神经功能缺损评分、脑组织含水量、脑梗死体积均显著增高(P<0.05,P<0.01);与模型组比较,各用药组的神经功能缺损评分、脑组织含水量、脑梗死体积和安全性评价指标(WBC、AST、APTT)均有不同程度降低(P<0.05,P<0.01);与依达拉奉组、疏血通组比较,联合用药组的神经功能缺损评分、脑组织含水量、脑梗死体积减少更明显(P<0.05,P<0.01),安全性指标差异无统计学意义。结论:依达拉奉联合疏血通在改善大鼠神经功能缺损症状、减少脑梗死体积、减轻脑水肿3个方面均优于依达拉奉组、疏血通组,且不良反应发生率低,安全性较好。
Objective: To evaluate the efficacy and safety of edaravone combined with Shuxuetong injection in the treatment of acute cerebral infarction in rats. Methods: SD rats were randomly divided into sham operation group, model group, edaravone group, Shuxuetong group, edaravone combined with Shuxuetong group. The rats were subjected to middle cerebral artery occlusion Each group was divided into 4 subgroups at different time points (1, 3, 5 and 7 days). The rats in each group received intraperitoneal injection of corresponding drugs, 1 / d, continuous administration of 1,3,5,7 d, the model group, sham operation group were given an equal volume of 0.9% sodium chloride solution, the observation group of neurological deficit score, cerebral infarction volume, brain (WBC), alanine aminotransferase (ALT), aspartate aminotransferase (AST), creatinine (Cr), blood urea nitrogen (BUN), creatine phosphokinase (CK), lactate Hydrogenase (LDH), activated partial thromboplastin time (APTT) and other changes. Results: Compared with the sham operation group, the neurological deficit score, brain water content and infarct volume in the other groups were significantly increased (P <0.05, P <0.01). Compared with the model group, the neurological deficit score (WBC, AST, APTT) were decreased to some extent (P <0.05, P <0.01). Compared with Edaravone group and Shuxuetong group, the levels of brain water content, cerebral infarction volume and safety index Neurological deficit score, water content of brain tissue and volume of cerebral infarction in treatment group decreased more significantly (P <0.05, P <0.01), and there was no significant difference in safety index. Conclusion: Edaravone combined with Shuxuetong is better than edaravone and shuixuentong in improving neurological deficit symptoms, reducing cerebral infarction volume and relieving cerebral edema, and the incidence of adverse reactions is low , Safety is better.